NCT04410809View on ClinicalTrials.gov

Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

TA-46

Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion

OTHER

Placebo

The same composition as the active medication but without the active substance TA-46

Trial Locations (1)

9728 NZ

PRA, Groningen

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04410809 - Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46 | Biotech Hunter | Biotech Hunter